153 related articles for article (PubMed ID: 33235338)
1. Clinical outcomes of Modified Collaborative Ocular Melanoma Study IRIS plaques for treatment of iris, iridociliary, and ciliary body melanoma.
Xu TT; Pulido JS; Deufel CL; Corbin KS; Petersen IA; Dalvin LA
Eye (Lond); 2021 Oct; 35(10):2754-2762. PubMed ID: 33235338
[TBL] [Abstract][Full Text] [Related]
2. Ruthenium plaque radiation therapy for iris and iridociliary melanomas.
Razzaq L; Keunen JE; Schalij-Delfos NE; Creutzberg CL; Ketelaars M; de Keizer RJ
Acta Ophthalmol; 2012 May; 90(3):291-6. PubMed ID: 20670343
[TBL] [Abstract][Full Text] [Related]
3. Plaque radiotherapy for residual or recurrent iris melanoma after surgical resection in 32 cases.
Shah SU; Shields CL; Bianciotto C; Emrich J; Komarnicky L; Shields JA
Ophthalmology; 2012 Apr; 119(4):838-842.e2. PubMed ID: 22133794
[TBL] [Abstract][Full Text] [Related]
4. Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement.
Gündüz K; Shields CL; Shields JA; Cater J; Freire JE; Brady LW
Arch Ophthalmol; 1999 Feb; 117(2):170-7. PubMed ID: 10037560
[TBL] [Abstract][Full Text] [Related]
5. Recurrence of iris melanoma after proton beam therapy.
Sandinha MT; Kacperek A; Errington RD; Coupland SE; Damato B
Br J Ophthalmol; 2014 Apr; 98(4):484-7. PubMed ID: 24414401
[TBL] [Abstract][Full Text] [Related]
6. Use of Ruthenium-106 Brachytherapy for Iris Melanoma: The Scottish Experience.
Agraval U; Sobti M; Russell HC; Lockington D; Ritchie D; Cauchi P; Kemp EG; Chadha V
Br J Ophthalmol; 2018 Jan; 102(1):74-78. PubMed ID: 28600302
[TBL] [Abstract][Full Text] [Related]
7. Ruthenium-106 brachytherapy for iris and iridociliary melanomas.
Marinkovic M; Horeweg N; Laman MS; Bleeker JC; Ketelaars M; Peters FP; Luyten GPM; Creutzberg CL
Br J Ophthalmol; 2018 Aug; 102(8):1154-1159. PubMed ID: 29122824
[TBL] [Abstract][Full Text] [Related]
8. Iris melanoma management with iodine-125 plaque radiotherapy in 144 patients: impact of melanoma-related glaucoma on outcomes.
Shields CL; Shah SU; Bianciotto CG; Emrich J; Komarnicky L; Shields JA
Ophthalmology; 2013 Jan; 120(1):55-61. PubMed ID: 22980742
[TBL] [Abstract][Full Text] [Related]
9. Proton beam radiotherapy of diffuse iris melanoma in 54 patients.
Willerding GD; Cordini D; Hackl C; Karle B; Lakotka N; Foerster MH; Bechrakis NN; Heufelder J; Moser L; Joussen AM
Br J Ophthalmol; 2015 Jun; 99(6):812-6. PubMed ID: 25505288
[TBL] [Abstract][Full Text] [Related]
10. High-frequency ultrasound characteristics of 24 iris and iridociliary melanomas: before and after plaque brachytherapy.
Finger PT; Reddy S; Chin K
Arch Ophthalmol; 2007 Aug; 125(8):1051-8. PubMed ID: 17698751
[TBL] [Abstract][Full Text] [Related]
11. Lack of radiation maculopathy after palladium-103 plaque radiotherapy for iris melanoma.
Yousef YA; Finger PT
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1107-12. PubMed ID: 22172910
[TBL] [Abstract][Full Text] [Related]
12. Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications.
Shields CL; Naseripour M; Shields JA; Freire J; Cater J
Am J Ophthalmol; 2003 May; 135(5):648-56. PubMed ID: 12719072
[TBL] [Abstract][Full Text] [Related]
13. Proton beam irradiation of uveal melanoma involving the iris, ciliary body and anterior choroid without surgical localisation (light field).
Oxenreiter MM; Lane AM; Aronow MB; Shih H; Trofimov AV; Kim IK; Gragoudas ES
Br J Ophthalmol; 2022 Apr; 106(4):518-521. PubMed ID: 33355171
[TBL] [Abstract][Full Text] [Related]
14. Alternative dose for choroidal melanoma treated with an iodine-125 radioactive plaque: a single-institution retrospective study.
Saconn PA; Gee CJ; Greven CM; McCoy TP; Ekstrand KE; Greven KM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):844-8. PubMed ID: 20171804
[TBL] [Abstract][Full Text] [Related]
15. Plaque radiation therapy for malignant melanoma of the iris and ciliary body.
Finger PT
Am J Ophthalmol; 2001 Sep; 132(3):328-35. PubMed ID: 11530044
[TBL] [Abstract][Full Text] [Related]
16. The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma: IV. Local Treatment Failure and Enucleation in the First 5 Years after Brachytherapy. COMS Report No. 19.
Jampol LM; Moy CS; Murray TG; Reynolds SM; Albert DM; Schachat AP; Diddie KR; Engstrom RE; Finger PT; Hovland KR; Joffe L; Olsen KR; Wells CG;
Ophthalmology; 2020 Apr; 127(4S):S148-S157. PubMed ID: 32200815
[TBL] [Abstract][Full Text] [Related]
17. Iris Melanoma Outcomes Based on the American Joint Committee on Cancer Classification (Eighth Edition) in 432 Patients.
Shields CL; Di Nicola M; Bekerman VP; Kaliki S; Alarcon C; Fulco E; Shields JA
Ophthalmology; 2018 Jun; 125(6):913-923. PubMed ID: 29342436
[TBL] [Abstract][Full Text] [Related]
18. Primary iris melanoma: diagnostic features and outcome of conservative surgical treatment.
Conway RM; Chua WC; Qureshi C; Billson FA
Br J Ophthalmol; 2001 Jul; 85(7):848-54. PubMed ID: 11423461
[TBL] [Abstract][Full Text] [Related]
19. Ciliary body melanoma with limited nodular extrascleral extension and diffuse iris-angle infiltration treated by whole anterior segment plaque radiotherapy.
Gray ME; Corrêa ZM; Augsburger JJ; Barrett W
Int Ophthalmol; 2007 Aug; 27(4):273-6. PubMed ID: 17468833
[TBL] [Abstract][Full Text] [Related]
20. (106)Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence.
Barker CA; Francis JH; Cohen GN; Marr BP; Wolden SL; McCormick B; Abramson DH
Brachytherapy; 2014; 13(6):584-90. PubMed ID: 24880583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
